Drug Approval | October 14, 2021
IOL receives Korean FDA approval
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
Subscribe To Our Newsletter & Stay Updated
